Publications

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications

Faiz M, Riedemann M, Jutzi JS, Mullally A. Curr Hematol Malig Rep. 2025 Jan 8;20(1):4. doi: 10.1007/s11899-024-00749-4. PMID: 39775969.

Evolution of myeloproliferative neoplasms from normal blood stem cells

Hormoz S, Sankaran VG, Mullally A.  Haematologica. 2024 Dec 5. doi: 10.3324/haematol.2023.283951. Epub ahead of print. PMID: 39633553.

Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.

Kramer F, Mullally A.J Cell Mol Med. 2023 Aug 7;28(5):e17896. doi: 10.1111/jcmm.17896. Online ahead of print.
PMID: 37551061 Free PMC article. Review.

Biology and therapeutic targeting of molecular mechanisms in MPNs.

How J, Garcia JS, Mullally A.Blood. 2023 Apr 20;141(16):1922-1933. doi: 10.1182/blood.2022017416.
PMID: 36534936 Free PMC article. Review.

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.

Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A.Leukemia. 2023 Feb;37(2):359-369. doi: 10.1038/s41375-022-01781-0. Epub 2022 Dec 6.
PMID: 36473980
View more on PubMed